FDA Updates SMA Treatment Dosing - Top_Thought_Leaders - MDSpire

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

  • By

  • Kathryn Wighton

  • March 30, 2026

  • 2 min

Share

Top Thought Leaders in Urology

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Updates SMA Treatment Dosing

  • by Kathryn Wighton

  • March 30, 2026

Related Content

Sleep Program Shifted Teen Circadian Timing

Two-week chronotherapy trial evaluates circadian phase, sleep duration, and alignment outcomes.

AAP Updates Pediatric Office Emergency Readiness

Guidance addresses office readiness, recommended equipment and medications, and team communication processes for infrequent but high-acuity emergencies.

Online Program Eases Pediatric Trauma Stress

Randomized trial evaluated therapist-assisted intervention among pediatric patients with persistent symptoms 1 month following trauma